CSBR

+ Watchlist + Portfolio

Champions Oncology, Inc.

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.94
52-Week Range: $4.59 – $8.31
Market Cap: $70.08M
P/E (TTM): —
EPS (TTM): -0.07
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 17.98
PEG Ratio: —
Return on Equity: -28.38%
Return on Assets: -1.82%
Gross Margin: 49.82%
Operating Margin: -2.69%
Profit Margin: -1.87%
Current Ratio: 1.03
Debt/Equity: 2.46
Total Debt: $10.97M
Free Cash Flow: $-5.49M
Revenue Growth: 8.80%
Earnings Growth: —
Enterprise Value: $75.94M

CSBR Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$53.87M	$50.16M	$56.94M	$59.42M
Cost of Revenue	$29.53M	$29.40M	$28.39M	$30.90M
Gross Profit	$24.34M	$20.75M	$28.55M	$28.52M
Research & Development	$11.54M	$9.54M	$6.83M	$9.08M
Selling, General & Admin	$17.24M	$18.13M	$16.88M	$20.47M
Operating Expenses	$28.79M	$27.68M	$23.71M	$29.55M
Operating Income	-$4.45M	-$6.92M	$4.85M	-$1.03M
EBITDA	-$2.20M	-$5.05M	$6.49M	$348.00K
Pretax Income	-$5.27M	-$7.31M	$4.63M	-$929.00K
Income Tax	$68.00K	-$32.00K	-$75.00K	$246.00K
Net Income	-$5.33M	-$7.28M	$4.70M	-$1.18M
Diluted EPS	-0.39	-0.54	0.33	-0.08
Diluted Shares	13.54M	13.55M	14.27M	13.83M

CSBR Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$10.12M	$2.62M	$9.79M	$4.87M
Receivables	$8.01M	$9.53M	$11.20M	$13.18M
Current Assets	$19.46M	$13.64M	$22.36M	$19.22M
Total Assets	$34.31M	$26.13M	$32.34M	$26.99M
Current Liabilities	$21.73M	$21.54M	$23.85M	$19.92M
Total Debt	$8.60M	$7.43M	$6.11M	$4.51M
Total Liabilities	$29.68M	$28.04M	$28.57M	$22.92M
Retained Earnings	-$77.32M	-$84.59M	-$79.89M	-$81.07M
Shareholders' Equity	$4.64M	-$1.90M	$3.77M	$3.94M
Working Capital	-$2.28M	-$7.90M	-$1.50M	-$703.00K

CSBR Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	$3.97M	-$6.14M	$7.39M	-$4.47M
Capital Expenditure	-$2.87M	-$836.00K	-$389.00K	-$564.00K
Free Cash Flow	$1.10M	-$6.97M	$7.00M	-$5.04M
Depreciation & Amortisation	$2.25M	$1.87M	$1.64M	$1.38M
Stock-Based Compensation	$864.00K	$1.12M	$654.00K	$1.24M
Investing Cash Flow	-$2.87M	-$836.00K	-$389.00K	-$540.00K
Financing Cash Flow	$11.00K	-$527.00K	$170.00K	$99.00K
Share Repurchases	-$74.00K	-$634.00K	$0.00	—
Net Change in Cash	$1.11M	-$7.50M	$7.17M	-$4.91M

CSBR Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Revenue	$12.36M	$13.99M	$15.04M	$16.56M	$13.84M	$15.23M
Cost of Revenue	$7.27M	$8.00M	$7.26M	$8.83M	$6.81M	$7.53M
Gross Profit	$5.08M	$6.00M	$7.77M	$7.72M	$7.03M	$7.70M
Research & Development	$1.96M	$2.08M	$2.62M	$2.27M	$2.12M	$2.34M
Selling, General & Admin	$4.83M	$4.42M	$4.97M	$5.64M	$5.43M	$5.76M
Operating Expenses	$6.80M	$6.51M	$7.59M	$7.91M	$7.55M	$8.11M
Operating Income	-$1.71M	-$507.00K	$185.00K	-$187.00K	-$521.00K	-$409.00K
EBITDA	-$1.32M	-$149.00K	$542.00K	$154.00K	-$200.00K	-$95.00K
Pretax Income	-$1.96M	-$452.00K	$255.00K	-$237.00K	-$495.00K	-$415.00K
Income Tax	-$129.00K	$14.00K	$18.00K	$42.00K	$172.00K	$11.00K
Net Income	-$1.83M	-$466.00K	$299.00K	-$279.00K	-$667.00K	-$426.00K
Diluted EPS	-0.13	-0.03	0.02	-0.02	—	-0.03
Diluted Shares	13.75M	13.79M	14.46M	13.89M	—	13.90M

CSBR Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Cash & Equivalents	$9.79M	$10.32M	$8.52M	$7.13M	$4.87M	$4.36M
Receivables	$11.20M	$9.47M	$11.54M	$12.07M	$13.18M	$13.60M
Current Assets	$22.36M	$21.01M	$21.33M	$20.18M	$19.22M	$19.29M
Total Assets	$32.34M	$30.55M	$30.16M	$28.45M	$26.99M	$33.29M
Current Liabilities	$23.85M	$22.70M	$22.14M	$20.68M	$19.92M	$18.73M
Total Debt	$6.11M	$5.75M	$5.27M	$4.89M	$4.51M	$10.52M
Total Liabilities	$28.57M	$27.01M	$25.93M	$24.07M	$22.92M	$28.83M
Retained Earnings	-$79.89M	-$80.36M	-$80.12M	-$80.40M	-$81.07M	-$81.49M
Shareholders' Equity	$3.77M	$3.51M	$4.17M	$4.28M	$3.94M	$3.89M
Working Capital	-$1.50M	-$1.68M	-$809.00K	-$492.00K	-$703.00K	$563.00K

CSBR Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Operating Cash Flow	$6.87M	$600.00K	-$1.74M	-$1.34M	-$2.00M	-$492.00K
Capital Expenditure	-$253.00K	-$46.00K	-$242.00K	-$37.00K	-$239.00K	-$55.00K
Free Cash Flow	$6.62M	$554.00K	-$1.98M	-$1.38M	-$2.24M	-$547.00K
Depreciation & Amortisation	$394.00K	$358.00K	$357.00K	$341.00K	$321.00K	$314.00K
Stock-Based Compensation	$131.00K	$208.00K	$249.00K	$423.00K	$357.00K	$766.00K
Investing Cash Flow	-$253.00K	-$46.00K	-$242.00K	-$14.00K	-$238.00K	-$55.00K
Financing Cash Flow	-$32.00K	-$14.00K	$168.00K	-$36.00K	-$19.00K	$33.00K
Share Repurchases	$0.00	—	—	—	—	—
Net Change in Cash	$6.58M	$540.00K	-$1.81M	-$1.39M	-$2.25M	-$514.00K

Market Snapshot

About

Champions Oncology, Inc. is a technology-enabled oncology solutions company providing drug development services to pharmaceutical and biotechnology companies. Headquartered in Hackensack, New Jersey, the company operates the TumorGraft platform, which uses patient-derived tumor models to predict clinical outcomes and optimize cancer drug development. Champions Oncology offers preclinical services including efficacy studies, biomarker discovery, and personalized medicine approaches. The company's platform helps accelerate oncology drug development by providing more predictive preclinical data.